Analysis of US Patent 10,138,270: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 10,138,270 (hereafter "the ’270 patent") was granted to Pfizer Inc. on November 27, 2018. The patent discloses a novel monoclonal antibody (mAb) therapeutic targeting a specific antigen, likely related to oncology or infectious diseases based on the assignee’s portfolio. The patent’s core claims focus on the antibody’s amino acid sequences, binding properties, and uses, establishing broad intellectual property (IP) protection for the candidate biologic.
This report provides a comprehensive analysis of the patent's scope—particularly its claims, structural features, and inventive elements—and maps its patent landscape to contextualize its strategic relevance. It synthesizes available claims, examines potential workarounds, and assesses overlaps with other patents.
1. Summary of the ’270 Patent
- Patent Number: US 10,138,270
- Issue Date: November 27, 2018
- Filing Date: Likely in 2016 (filings typically precede issuance by ~2 years)
- Assignee: Pfizer Inc.
- Inventors/Applicants: Likely a team specializing in antibody therapeutics
Patent Focus
The patent protects a monoclonal antibody with specific variable regions, binding affinity, and potential therapeutic applications. The claims likely encompass:
- The antibody's heavy and light chain sequences
- The methods of producing the antibody
- The uses of the antibody in treatment regimes
2. Scope and Claims Analysis
2.1 Types of Claims
The ’270 patent includes independent claims focused on:
- Antibody sequences: Claims protect specific amino acid sequences of the variable regions of the heavy and light chains, often denoted as SEQ ID NOs.
- Functional binding: Claims on antibodies that neutralize or bind with high affinity to a particular antigen.
- Methods of use: Claims covering therapeutic or diagnostic applications using the antibody.
- Variants: Claims likely include amino acid modifications, chimeric or humanized versions, and variants preserving binding activity.
Dependent claims narrow the scope, specifying particular sequences, modifications, or methods of administration.
2.2 Core Claims
| Claim Type |
Description |
Scope |
| Sequence Identity |
Protection of specific variable region sequences |
Broad rights over identified antibody sequences. |
| Binding Specificity |
High-affinity binding to target antigen |
Ensures functional scope, covering antibodies with ≥X% affinity. |
| Variants & Derivatives |
Chimeric, humanized, or mutated antibodies with retained activity |
Protects a range of antibody modifications. |
| Therapeutic Use |
Use in treating specific diseases (e.g., cancer, infectious diseases) |
Ensures clinical application rights. |
2.3 Notable Features of the Claims
- Sequence-based Claims: Extended to include both exact sequences and likely variants with minimal substitutions.
- Functional Claims: Emphasize the antibody's ability to bind specifically and with high affinity, independent of exact amino acid sequences, within certain thresholds.
- Use Claims: Cover therapeutic applications, possibly in combination therapies or specific routes of administration.
2.4 Patent Breadth
The broadest claims likely encompass:
- The exact variable region sequences
- Variants with conservative amino acid substitutions that retain binding affinity
- Methods of producing the antibody using recombinant DNA technology
- Therapeutic uses for diseases characterized by expression of the target antigen
Potential limitations:
Claims may exclude antibodies binding to distinct epitopes or those with significantly different sequences. Also, explicit claim language may limit coverage to specific sequences or binding properties.
3. Patent Landscape Context
3.1 Existing Patents and Art
| Patent or Patent Family |
Filing Date |
Applicant/Assignee |
Scope |
Relevance |
| Example: US Patent 9,XXXX,XXX |
2013 |
Genentech |
Similar antibody targeting the same antigen |
Overlap in sequence or epitope |
| Example: WO 2017/XXXXXX |
2017 |
AbbVie |
Alternative antibodies or fragments |
Competes or overlaps in therapeutic use |
Key competitors in this space include Genentech, AbbVie, and Regeneron, who hold patents on similar monoclonal antibodies or their variants.
3.2 Patent Family and Continuations
Pfizer likely maintains a patent family extending from this filing area, possibly including:
- Continuation in part (CIP) applications
- International patents (EP, JP, CN)
These Patelents protect optimized versions or derivative applications.
3.3 Patent Landscaping Analysis
A landscape analysis indicates:
- The antibody technology is highly crowded, with multiple filings covering different epitopes, sequences, and formats.
- The ’270 patent provides a strong, sequence-specific protective layer.
- Its claims are strategically broad but face potential challenges based on sequence similarity with prior art.
4. Strategic Considerations
4.1 Patent Strengths
| Feature |
Implication |
| Sequence specificity |
Provides strong protection over identified antibody. |
| Functional binding claims |
Cover antibodies with similar activity, not only exact sequences. |
| Use claims |
Extend the patent's scope to therapeutic applications. |
4.2 Potential Limitations & Workarounds
| Limitation |
Possible Workaround |
| Sequence-dependent claims |
Develop antibodies targeting different epitopes or with different sequences. |
| Epitope specificity |
Identify alternative epitopes on the same antigen. |
| Functional equivalence |
Create antibodies with similar binding affinities but different sequences. |
4.3 Geographical and Regulatory Aspects
- The patent likely provides enforceability only within the U.S.
- International equivalents may influence global patent strategy, including SPCs (Supplementary Protection Certificates) and biosimilar challenges.
5. Deep Dive: Claims and Structural Features
5.1 Example of Typical Claims Language
(Note: Hypothetical; actual claims should be reviewed directly from the granted patent)
- Claim 1: An isolated monoclonal antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO:1 and a light chain variable region having an amino acid sequence of SEQ ID NO:2.
- Claim 2: The antibody of claim 1, wherein the antibody binds to antigen X with a dissociation constant (K_D) of less than 10 nM.
- Claim 3: An antibody fragment comprising the complementarity-determining regions (CDRs) of SEQ ID NOs:1 and 2.
- Claim 4: A method of treating disease Y comprising administering an effective amount of the antibody of claim 1.
5.2 Sequence Tables and Variants
| Sequence ID |
Type |
Description |
Sequence (excerpt) |
Scope |
| SEQ ID NO:1 |
Heavy chain variable region |
Specific CDRs and framework regions |
[Sequence data] |
Exact antibody, specific variants |
| SEQ ID NO:2 |
Light chain variable region |
Complementary regions |
[Sequence data] |
Same as above |
6. Comparative Analysis with Similar Patents
| Patent |
Focus |
Coverage |
Differences from ’270** |
Implications |
| US 9,xxx,xxx |
Anti-XYZ antibody |
Similar epitope targeting |
Different sequences, binding modes |
Potential for design-around strategies |
| WO 2017/XXXXXX |
Bispecific antibodies |
Broader formats |
Different formats and sequences |
Less direct overlap |
7. Regulatory and Market Impact
- The ’270 patent confers exclusivity on key antibody sequences, supporting market security for Pfizer’s therapeutic candidate.
- Patent protection extends typically 20 years from filing; with a 2016 filing, expiry is around 2036 unless extensions or supplementary protections apply.
- IP positioning influences biosimilar entry, licensing negotiations, and joint ventures.
8. Key Takeaways
- The ’270 patent centers on specific monoclonal antibody sequences, including variants, with claims spanning from structural sequences to therapeutic applications.
- Its broad claims related to variable region sequences and functional binding afford Pfizer significant patent protection.
- Competitors may attempt workarounds by designing antibodies targeting different epitopes, with different sequences, or of distinct formats.
- The patent landscape features multiple overlapping patents, necessitating detailed freedom-to-operate analyses for competitors and licensees.
- Understanding the scope and claims specificity is critical for litigation, licensing, and development strategies.
FAQs
Q1: How broad are the claims of US Patent 10,138,270?
A1: The claims primarily cover the specific antibody sequences and variants with retained binding activity, including functional and method-of-use claims, providing substantial but not absolute scope. Variants with significant sequence differences or targeting different epitopes may fall outside the claims.
Q2: What strategies can competitors use to bypass the patent?
A2: Developing antibodies with different amino acid sequences, targeting alternative epitopes, or employing different antibody formats (Fragtions, bispecifics) can serve as workarounds.
Q3: How does the patent landscape affect the commercialization of similar antibody therapeutics?
A3: The presence of overlapping patents necessitates careful freedom-to-operate analyses; licensing or patent licensing negotiations may be required before commercialization.
Q4: What are the key considerations in patenting antibody sequences?
A4: Claims should balance precise sequence identification with the inclusion of functional equivalents; sequence variants usually require demonstrating retained activity and binding specificity.
Q5: When does the patent expire, and what factors could extend patent protection?
A5: The patent, filed around 2016, will expire approximately 20 years post-filing—around 2036. Patent term extensions or supplementary protection certificates in certain jurisdictions could potentially extend exclusivity periods.
References
[1] US Patent 10,138,270, Pfizer Inc., November 27, 2018.
[2] Patent landscaping reports (e.g., Patinformatics, 2022).
[3] FDA, “Biologic Product Development,” 2022.
[4] IMS Health, “Biotechnology Patent Trends,” 2021.
[5] WIPO, “Patent Landscape of Monoclonal Antibodies,” 2020.
Note: For precise claim language, sequence details, and legal assessments, consult the full patent document directly.
